On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - Hier 11:01
FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. Selpercatinib received accelerated approval for this indication for [...]
Articles similaires
FDA Grants Traditional Approval to Retevmo (selpercatinib) for Medullary Thyroid Cancer with a RET Mutation
drugs.com - 27/Sep 03:09
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
drugs.com - 18/Sep 23:09
RAHWAY, N.J.--(BUSINESS WIRE) September 18, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S....
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
zacks.com - 27/Sep 14:19
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients...
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
zacks.com - 19/Sep 14:21
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given...
Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer
drugs.com - 26/Sep 15:09
THURSDAY, Sept. 26, 2024 -- Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive Diagnostic for Enhanced Diagnosis of Coronary Artery Disease
drugs.com - 27/Sep 20:09
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE) September 27, 2024 --GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration...
Incidence of Cardiovascular Disease Higher for Seniors With Cancer
drugs.com - 23/Sep 16:09
MONDAY, Sept. 23, 2024 -- The incidence of a composite cardiovascular disease (CVD) end point is increased among older adults with cancer, especially...
FDA Approves EBGLYSS Drug for Atopic Dermatitis in Adults and Children
medindia.net - 27/Sep 13:55
Highlights: EBGLYSS targets IL-13 to reduce eczema inflammation and itching FDA approval was based on successful
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
drugs.com - 18/Sep 22:23
WEDNESDAY, Sept. 18, 2024 -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and...
Les derniers communiqués
-
Aucun élément